These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 38687017)

  • 21. Determination of antibiotic efficacy against Bacillus anthracis in a mouse aerosol challenge model.
    Heine HS; Bassett J; Miller L; Hartings JM; Ivins BE; Pitt ML; Fritz D; Norris SL; Byrne WR
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1373-9. PubMed ID: 17296745
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic-pharmacodynamic analysis of fluoroquinolones against Bacillus anthracis.
    Kihira T; Sato J; Shibata T
    J Infect Chemother; 2004 Apr; 10(2):97-100. PubMed ID: 15160302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bacillus anthracis protective antigen kinetics in inhalation spore-challenged untreated or levofloxacin/ raxibacumab-treated New Zealand white rabbits.
    Corey A; Migone TS; Bolmer S; Fiscella M; Ward C; Chen C; Meister G
    Toxins (Basel); 2013 Jan; 5(1):120-38. PubMed ID: 23344456
    [TBL] [Abstract][Full Text] [Related]  

  • 24.
    Martchenko Shilman M; Bartolo G; Alameh S; Peterson JW; Lawrence WS; Peel JE; Sivasubramani SK; Beasley DWC; Cote CK; Demons ST; Halasahoris SA; Miller LL; Klimko CP; Shoe JL; Fetterer DP; McComb R; Ho CC; Bradley KA; Hartmann S; Cheng LW; Chugunova M; Kao CY; Tran JK; Derbedrossian A; Zilbermintz L; Amali-Adekwu E; Levitin A; West J
    ACS Infect Dis; 2021 Aug; 7(8):2176-2191. PubMed ID: 34218660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibiotics cure anthrax in animal models.
    Weiss S; Kobiler D; Levy H; Pass A; Ophir Y; Rothschild N; Tal A; Schlomovitz J; Altboum Z
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1533-42. PubMed ID: 21263056
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Teixobactin Provides Protection against Inhalation Anthrax in the Rabbit Model.
    Lawrence WS; Peel JE; Sivasubramani SK; Baze WB; Whorton EB; Beasley DWC; Comer JE; Hughes DE; Ling LL; Peterson JW
    Pathogens; 2020 Sep; 9(9):. PubMed ID: 32971758
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pathology of wild-type and toxin-independent Bacillus anthracis meningitis in rabbits.
    Sittner A; Bar-David E; Glinert I; Ben-Shmuel A; Weiss S; Schlomovitz J; Kobiler D; Levy H
    PLoS One; 2017; 12(10):e0186613. PubMed ID: 29088287
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of ETI-204 monoclonal antibody as an adjunct therapy in a New Zealand white rabbit partial survival model for inhalational anthrax.
    Biron B; Beck K; Dyer D; Mattix M; Twenhafel N; Nalca A
    Antimicrob Agents Chemother; 2015 Apr; 59(4):2206-14. PubMed ID: 25645849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
    Yağci R; Oflu Y; Dinçel A; Kaya E; Yağci S; Bayar B; Duman S; Bozkurt A
    Eye (Lond); 2007 Jul; 21(7):990-4. PubMed ID: 16732216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anthrax: safe treatment for children.
    Benavides S; Nahata MC
    Ann Pharmacother; 2002 Feb; 36(2):334-7. PubMed ID: 11847958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clindamycin Protects Nonhuman Primates Against Inhalational Anthrax But Does Not Enhance Reduction of Circulating Toxin Levels When Combined With Ciprofloxacin.
    Vietri NJ; Tobery SA; Chabot DJ; Ingavale S; Somerville BC; Miller JA; Schellhase CW; Twenhafel NA; Fetterer DP; Cote CK; Klimko CP; Boyer AE; Woolfitt AR; Barr JR; Wright ME; Friedlander AM
    J Infect Dis; 2021 Feb; 223(2):319-325. PubMed ID: 32697310
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
    Madhusudhan KT; Counts C; Lody C; Carter O; Dodson S; Ojha N
    Chemotherapy; 2003 Jul; 49(4):184-8. PubMed ID: 12886053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
    Caballero AR; Marquart ME; O'Callaghan RJ; Thibodeaux BA; Johnston KH; Dajcs JJ
    Curr Eye Res; 2006 Jan; 31(1):23-9. PubMed ID: 16421016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
    Thibodeaux BA; Dajcs JJ; Caballero AR; Marquart ME; Girgis DO; O'Callaghan RJ
    Curr Eye Res; 2004 May; 28(5):337-42. PubMed ID: 15287370
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy.
    Przybylski DJ; Reeves DJ
    Support Care Cancer; 2017 Dec; 25(12):3715-3721. PubMed ID: 28660351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus.
    Stergiopoulou T; Meletiadis J; Sein T; Papaioannidou P; Tsiouris I; Roilides E; Walsh TJ
    J Antimicrob Chemother; 2009 Feb; 63(2):343-8. PubMed ID: 19109335
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluation of the Efficacy of Doxycycline, Ciprofloxacin, Levofloxacin, and Co-trimoxazole Using
    Clay KA; Hartley MG; Armstrong S; Bewley KR; Godwin K; Rayner E; Vipond J; Bailey M; Atkins TP; Norville IH
    Antimicrob Agents Chemother; 2021 Oct; 65(11):e0067321. PubMed ID: 34370577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effective antiprotease-antibiotic treatment of experimental anthrax.
    Popov SG; Popova TG; Hopkins S; Weinstein RS; MacAfee R; Fryxell KJ; Chandhoke V; Bailey C; Alibek K
    BMC Infect Dis; 2005 Apr; 5():25. PubMed ID: 15819985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin.
    García-Sáenz MC; Arias-Puente A; Fresnadillo-Martinez MJ; Carrasco-Font C
    J Cataract Refract Surg; 2001 Dec; 27(12):1969-74. PubMed ID: 11738912
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
    Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
    J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.